SCHEMBL2867237

SCHEMBL2867237

CN1CCN(C(=O)c2ccc3[nH]nc(-c4cccc(F)c4)c3c2)CC1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAP4K1 Q92918 1/20 0.52
DYRK1A Q13627 1/20 0.51
ABL1 P00519 5/20 0.50
BCR P11274 5/20 0.50
ALDH1A1 P00352 1/20 0.48
MAPT P10636 1/20 0.48
MAPK1 P28482 1/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
MAPK10 P53779 1/20 0.48
FLT3 P36888 1/20 0.48
NTRK1 P04629 1/20 0.47
MAP4K4 O95819 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.46
POLB P06746 1/20 0.46
KDM4E B2RXH2 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
MGLL Q99685 1/20 0.45
AURKB Q96GD4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2870409 0.87 JAK2 (0.56) DYRK1AABL1BCRALDH1A1MAPK10
SCHEMBL2864990 0.82 CYP3A4 (0.54) ABL1BCRALDH1A1MAPK1MEN1
SCHEMBL31172167 0.80 ALDH1A1 (0.51) MAP4K1ALDH1A1MAPTMAPK10FLT3
SCHEMBL2858476 0.79 MAP2K4 (0.68) MAPK1NTRK1
SCHEMBL5376946 0.78 MAPK8 (0.54) MAP4K1DYRK1AMAPK10MAP4K4KDM4E
SCHEMBL5801740 0.78 MAP2K4 (0.65) MAPK1MAPK10NTRK1
SCHEMBL2860913 0.78 MAP2K4 (0.61) MAPTMAPK1MEN1KMT2ANTRK1
SCHEMBL5378619 0.78 ABL1 (0.57) ABL1BCRALDH1A1MAPTMAPK1
Ethylene SCHEMBL27536148 0.77 MAP2K4 (0.65) MAPK1NTRK1
SCHEMBL1225812 0.76 PDPK1 (0.61) MAPK10FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
US-6982274-B2 1H-indazole compound EISAI CO., LTD. (JP) 2006-01-03 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed
US-20040127538-A1 Novel 1h-indazole compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-07-01 US disclosed
EP-1380576-A1 NOVEL 1H-INDAZOLE COMPOUND Eisai Co., Ltd. (JP) 2004-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 MAP4K1 43/4885DYRK1A 1216/4885ABL1 92/4885
US-20040127538-A1 Novel 1h-indazole compound MAPK1, MAPK14, MAPK3 MAP4K1 45/4885DYRK1A 2459/4885ABL1 150/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 MAP4K1 43/4885DYRK1A 1216/4885ABL1 92/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.